HealthFinSMEsabout 1 hour ago
Oyster Therapeutics Raises $60M Series A
2 min read
London-based Oyster Therapeutics closed a $60m Series A-2 financing led by 4BIO Capital with participation from Eli Lilly and Company. The company plans to use funds to advance oral tau degraders for Alzheimer's treatment and develop its SELFTAC platform.
Level
Hype check
Tap to vote and see what everyone thinks.
